Iovance Biotherapeutics Q3 2023 Earnings Report

Iovance Biotherapeutics EPS Results

• Actual EPS: -$0.46
• Consensus EPS: -$0.46
• Beat/Miss: Met Expectations
• One Year Ago EPS: -$0.63

Iovance Biotherapeutics Revenue Results

• Actual Revenue: $0.47 million
• Expected Revenue: $4.50 million
• Beat/Miss: Missed by -$4.03 million
• YoY Revenue Growth: N/A

Iovance Biotherapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/7/2023
• Time: After Market Closes

Iovance Biotherapeutics (NASDAQ:IOVA), a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.